Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL cer...(ive Officer of Cardium Therapeutics and ...)

Date:7/14/2008

ive Officer of Cardium Therapeutics and InnerCool Therapies. "This is the first UL global certification for an endovascular thermal regulating system and further confirms the technology leadership position that InnerCool is establishing with the RapidBlue System. With commercialization agreements in place with leading distributors in the European Union, we look forward to expanding our distribution activities to include our RapidBlue System."

InnerCool's RapidBlue System is a thermal regulating system designed to manage and control patient body temperature. The system automatically cools or warms patients, as necessary, to maintain desired body temperature. RapidBlue provides rapid or gradual temperature control for all patient sizes and its closed loop catheter based system modulates whole body temperature without fluid introduction or exchange by circulating cool or warm saline within the interior of the catheter. Unlike various other systems, RapidBlue is powerful enough to quickly cool awake patients and can eliminate the need to use paralytic agents. The system includes a programmable console with an enhanced user-friendly interface and touch-panel screen.

The RapidBlue System powers InnerCool's low-profile flexible Accutrol(R) catheter which can quickly modulate patient temperature at cooling rates of 4-5 degrees Celsius per hour. The Accutrol catheter contains an integrated temperature sensor capable of accurately measuring core body temperature to within 0.1 degree Celsius of pulmonary artery temperature. Its novel software control algorithm provides automated and precise body temperature control, eliminating the use of peripheral temperature probes which are generally slow to respond to changes in core body temperature.

The Company also announced that Underwriters Laboratories, Inc. (UL) completed a national and international conformity assessment for the RapidBlue System and concluded that it meets all of the applicable requirements of
'/>"/>

SOURCE Cardium Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Cardium Announces Follow-On Direct Investment by Institutional Investor
2. Cardium Selected for Inclusion in Russell Microcap Index
3. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
4. Cardium Launches New AWARE Clinical Study Website
5. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
6. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
9. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
10. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
11. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion